Publications by authors named "Lucas Peter"

Claim this Profile
E
ENDORISK-2: A personalized Bayesian network for preoperative risk stratification in endometrial cancer, integrating molecular classification and preoperative myometrial invasion assessment.
Marike S Lombaers, Casper Reijnen, Ally Sprik, Petra Bretová, Marcel Grube, Peter Bronsert, Peter J F Lucas

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Peter C Lucas

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Neoplasia in Birt-Hogg-Dubé Syndrome: Integrated Histopathologic, Bulk, and Single-cell Transcriptomic Analysis.
Sounak Gupta, Surendra Dasari, Rachel R Warren, Wei Shen, Rhianna M Urban, Peter C Lucas

Eur Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Federated causal discovery with missing data in a multicentric study on endometrial cancer.
Alessio Zanga, Alice Bernasconi, Peter J F Lucas, Hanny Pijnenborg, Casper Reijnen

J Biomed Inform· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of tissue and clinical thrombectomy outcome in acute ischaemic stroke using deep learning.
Marie-Sophie von Braun, Kristin Starke, Lucas Peter, Daniel Kürsten, Florian Welle

Brain· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial.
Mark Basik, Reena S Cecchini, Jennifer F De Los Santos, Heidi R Umphrey, Thomas B Julian, Peter C Lucas

JAMA Surg· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 breast cancer that limits trastuzumab deruxtecan efficacy.
Dong Hu, Xiaoshuang Lyu, Zheqi Li, Prasanna Ekambaram, Anushka Dongre, Peter C Lucas

Nat Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
Eleftherios P Mamounas, Hanna Bandos, Julia R White, Thomas B Julian, Atif J Khan, Peter C Lucas

N Engl J Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma.
Heejae Kang, Lisa M Maurer, Jing Cheng, Mei Smyers, Linda R Klei, Peter C Lucas

J Clin Invest· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune infiltration correlates with transcriptomic subtypes in primary estrogen receptor positive invasive lobular breast cancer.
Fangyuan Chen, Sayali Onkar, Jian Zou, Yujia Li, Haley Arbore, Peter C Lucas

NPJ Precis Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
Priya Rastogi, Hanna Bandos, Peter C Lucas, Laura J van 't Veer, Jia-Perng J Wei

J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mDia2 is an important mediator of MRTF-A-dependent regulation of breast cancer cell migration.
Ian Eder, Virginia Yu, Jacob Antonello, Fangyuan Chen, David Gau, Peter C Lucas

Mol Biol Cell· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction to the special issue on IEEE CBMS 2022 mining healthcare: AI and machine learning for biomedicine.
Rosa Sicilia, Linlin Shen, Alejandro Rodríguez-González, K C Santosh, Peter J F Lucas

Artif Intell Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women.
Neil Carleton, Sanghoon Lee, Ruxuan Li, Jian Zou, Daniel D Brown, Peter C Lucas

bioRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Real-World Data to Causally Interpretable Models: A Bayesian Network to Predict Cardiovascular Diseases in Adolescents and Young Adults with Breast Cancer.
Alice Bernasconi, Alessio Zanga, Peter J F Lucas, Marco Scutari, Serena Di Cosimo

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression.
Juliana Hofstätter Azambuja, Saigopalakrishna S Yerneni, Lisa M Maurer, Hannah E Crentsil, Gabriela N Debom, Peter C Lucas

bioRxiv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer.
Fangyuan Chen, Sayali Onkar, Jian Zou, Yujia Li, Haley Arbore, Peter Lucas

Res Sq· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.
Osama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi, Jennifer M Atkinson, Celina G Kleer, Peter C Lucas

Proc Natl Acad Sci U S A· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics data.
Sanghoon Lee, Min Sun, Yiheng Hu, Yue Wang, Md N Islam, Peter C Lucas

BMC Bioinformatics· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.
Osama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi, Jennifer M Atkinson, Celina G Kleer, Peter C Lucas

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Peter C Lucas

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C Lucas

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, Tomás Pascual, Katherine A Hoadley, Peter C Lucas

JAMA Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero, Peter C Lucas

Breast Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero, Peter C Lucas

Breast Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis